The 2011 European Multidisciplinary Cancer Congress (ECCO-ESMO 2011), was held on 23–27 September 2011 in Stockholm, Sweden.
At ECCO-ESMO 2011, an AstraZeneca sponsored satellite symposium entitled ‘Advanced NSCLC: current concepts and future development of targeted treatment’ was held. The symposium was presented by an international panel of leading oncology experts:
- Dr Martin Reck (Chair), Germany
- Professor Fabrice Barlesi, France
- Dr James Yang, Taiwan
- Dr Bruce Johnson, USA
The symposium addressed recent developments in the molecular and genetic basis of advanced non-small-cell lung carcinoma (NSCLC), and considered tailored treatment strategies according to the EGFR mutation status of a patient's tumour. The symposium also explored the benefits of implementing individualised treatment strategies in the first-line setting and discussed the evidence available to guide treatment choices following disease progression. The faculty then considered how current treatment strategies for EGFR mutation-positive advanced NSCLC are evolving before discussing future treatment approaches. Interactive patient case studies focusing on EGFR-TKI treatment strategies were then presented and audience feedback was invited.
Click on the image below to view the full video and slides of the symposium
Click here to zoom
Please note that this symposium contains information about the first-line use of gefitinib in EGFR mutation-positive advanced NSCLC. Gefitinib product licences vary from country to country and not all licences include first-line use in EGFR mutation-positive advanced NSCLC. Please consult your local prescribing information.
Dr Martin Reck and Professor Fabrice Barlesi: Presentation highlights
Dr James Yang and Dr Bruce Johnson: Presentation highlights